Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7770754 | 1.00 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL570513 | 1.00 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL3422763 | 1.00 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL27671066 | 1.00 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10424903 | 0.84 | TSHR (0.38) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL16029586 | 0.82 | LMNA (0.34) | TSHRCHRM2CHRM4CHRM1MAPT | |
| SCHEMBL1515545 | 0.82 | — | — | |
| SCHEMBL4268651 | 0.81 | ALDH1A1 (0.39) | TSHR | |
| SCHEMBL4271249 | 0.81 | ALDH1A1 (0.39) | TSHR | |
| SCHEMBL4271254 | 0.81 | ALDH1A1 (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240117400-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | SEAGEN INC (US) | 2024-04-11 | — | — | US | disclosed |
| US-11891644-B2 | T cells with reduced surface fucosylation and methods of making and using the same | SEAGEN INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC (US) | 2023-02-23 | — | — | US | disclosed |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEAGEN INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3897664-A1 | CONTROLLED FUCOSYLATION OF ANTIBODIES | Seagen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113438951-A | Controlled fucosylation of antibodies | 西根股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEAGEN INC. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2020132096-A1 | CONTROLLED FUCOSYLATION OF ANTIBODIES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200149082-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | SEAGEN INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3634427-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | Seattle Genetics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2009135181-A2 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-1997045435-A1 | PROCESSES FOR THE SYNTHESIS OF SIALYL LEWISx COMPOUNDS | GLYCOMED, INCORPORATED (US) | 1997-12-04 | — | — | WO | disclosed |
| US-5654412-A | CONVERGENT SYNTHESIS VIA TWO DISACCHARIDE SUBCOMPONENTS; SIMPLIFICATION, HIGH YIELD | GLYCOMED INCORPORATED (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646123-A | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen | ALBERTA RESEARCH COUNCIL (CA) | 1997-07-08 | — | — | US | disclosed |
| US-5580858-A | Immunosuppressive and tolerogenic modified Lewisx compounds | ALBERTA RESEARCH COUNCIL (CA) | 1996-12-03 | — | — | US | disclosed |
| WO-1996016071-A1 | PROCESSES FOR THE SYNTHESIS OF 3'-SUBSTITUTED LEWISx COMPOUNDS | GLYCOMED, INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0650492-A1 | REDUCING INFLAMMATION BY TIME DEPENDENT ADMINISTRATION OF OLIGOSACCHARIDES GLYCOSIDES RELATED TO BLOOD GROUP DETERMINANTS | ALBERTA RESEARCH COUNCIL (CA) | 1995-05-03 | — | — | EP | disclosed |
| EP-0591254-A1 | IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWIS?X AND LEWIS?A COMPOUNDS | GLYCOMED INCORPORATED (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993024505-A1 | REDUCING INFLAMMATION BY TIME DEPENDENT ADMINISTRATION OF OLIGOSACCHARIDES GLYCOSIDES RELATED TO BLOOD GROUP DETERMINANTS | ALBERTA RESEARCH COUNCIL (CA) | 1993-12-09 | — | — | WO | disclosed |
| WO-1992022564-A1 | IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWISX AND LEWISA COMPOUNDS | ALBERTA RESEARCH COUNCIL (CA) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | TSHR 1665/4885CHRM2 4627/4885CHRM4 4254/4885 |
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | FUCA1, FUCA2, FUT4 | TSHR 3062/4885CHRM2 4795/4885CHRM4 4512/4885 |
| US-20240117400-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | CD4, FUCA2, CD2 | TSHR 1413/4885CHRM2 4763/4885CHRM4 4616/4885 |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | FUT5, FUCA2, FCGR3B | TSHR 1665/4885CHRM2 4627/4885CHRM4 4254/4885 |
| US-20200149082-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | CD4, FUCA2, CD2 | TSHR 1413/4885CHRM2 4763/4885CHRM4 4616/4885 |
| US-11891644-B2 | T cells with reduced surface fucosylation and methods of making and using the same | CD4, FUCA2, CD2 | TSHR 1413/4885CHRM2 4763/4885CHRM4 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.